Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.160 +33.3% NNX 0.035 +0.0% ABX 52.02 −0.4% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.73 +2.4% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.52 +1.4% SGZ 0.040 −11.1% GRSL 0.310 −3.1% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.160 +33.3% NNX 0.035 +0.0% ABX 52.02 −0.4% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.73 +2.4% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.52 +1.4% SGZ 0.040 −11.1% GRSL 0.310 −3.1% DEX 0.380 −1.3% WMS 0.040 +0.0%
Financings

Gemina Laboratories cancels $7-million financing

By The Northwire Desk — AI Analysis Oct 01, 2025 · 21:31 GLAB · 0.50 Gemina Laboratories Ltd
GLAB · Price

Executive Summary

  • Gemina Laboratories terminated its planned non‑brokered private placement of up to $7 million at $0.75 per common share.
  • The company is actively exploring alternative financing options.
  • Two directors, Martha Najib and Bola Grace, resigned from the board.

Key Details

  • Transaction Cancelled: Non‑brokered private placement originally announced for up to $7 M at a price of $0.75 per common share.
  • Reason for Termination: Inability to close on subscription commitments; company now seeking other financing alternatives.
  • Board Departures: Martha Najib and Bola Grace have resigned from the board of directors, effective immediately.
  • Future Plans: Management will continue to evaluate and pursue alternative sources of capital to fund ongoing operations and growth initiatives.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Gemina Laboratories Ltd

May 01, 2026 · 20:58

SEDAR Interim Financial Statements

None Dec 30, 2025 · 17:25

Gemina arranges minimum $1-million debenture offering

Financings Dec 30, 2025 · 09:45

Debenture Offering and Delisting

Financings